PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK.


Khan, Mohid S, Cook, Kathryn, Weickert, Martin O, Davies, Louise, Pritchard, D Mark ORCID: 0000-0001-7971-3561, Day, Melissa, Shah, Tahir, Hull, Diana, Caplin, Martyn, Back, Melissa et al (show 2 more authors) (2024) PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32 (3). p. 199.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Purpose</h4>PREF-NET reported patients' experience of Somatuline® (lanreotide) Autogel® (LAN) administration at home and in hospital among patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs).<h4>Methods</h4>PREF-NET was a multicentre, cross-sectional study of UK adults (aged ≥ 18 years) with GEP-NETs receiving a stable dose of LAN, which comprised of (1) a quantitative online survey, and (2) qualitative semi-structured interviews conducted with a subgroup of survey respondents. The primary objective was the description of overall patient preference for home versus hospital administration of LAN. Secondary objectives included describing patient-reported opinions on the experience and associated preference for each administration setting, and the impact on healthcare utilisation, societal cost, activities of daily living and health-related quality of life (HRQoL).<h4>Results</h4>In the primary analysis (80 patients; mean age 63.9 years), 98.7% (95% confidence interval [CI]: 96.1-100.0) of patients preferred to receive LAN at home, compared with 1.3% (95% CI: 0.0-3.9) who preferred the hospital setting. Among participants, over half (60.3%) received their injection from a non-healthcare professional. Most patients (79.5% [95% CI: 70.5-88.4]) reported a positive effect on HRQoL after the switch from hospital to home administration. Qualitative interviews (20 patients; mean age 63.6 years) highlighted that patients preferred home administration because it improved overall convenience; saved time and costs; made them feel more comfortable and relaxed, and less stressed; and increased confidence in their ability to self-manage their treatment.<h4>Conclusion</h4>Almost all patients preferred to receive LAN treatment at home rather than in hospital with increased convenience and psychological benefits reported as key reasons for this preference.

Item Type: Article
Uncontrolled Keywords: Humans, Neuroendocrine Tumors, Peptides, Cyclic, Somatostatin, Activities of Daily Living, Cross-Sectional Studies, Quality of Life, Adult, Middle Aged, Hospitals, Patient Preference, United Kingdom
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 09 Apr 2024 09:32
Last Modified: 09 Apr 2024 13:43
DOI: 10.1007/s00520-024-08377-7
Open Access URL: https://doi.org/10.1007/s00520-024-08377-7
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3180189
Dimensions
Altmetric
CORE (COnnecting REpositories)